DeepMed Research

Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

Completed

Conditions: Small Cell Lung Carcinoma
Carcinoma, Non-Small Cell Lung
Triple Negative Breast Carcinoma
Hepatocellular Carcinoma
Urothelial Carcinoma

Interventions: Drug: Atezolizumab

First Posted Date: 2017-07-28

Last Posted Date: 2022-08-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1758

Registration Number: NCT03232593

Locations: 🇰🇷
Dongnam Inst.of Radiological & Medical Sciences, Busan, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Inje university Haeundae Paik Hospital, Busan, Korea, Republic of

and more 52 locations

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Ipatasertib
Drug: Itraconazole

First Posted Date: 2017-07-19

Last Posted Date: 2017-11-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 15

Registration Number: NCT03222310

Locations: 🇺🇸
Covance Research Unit - Dallas, Dallas, Texas, United States

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: RO7049665
Biological: Placebo

First Posted Date: 2017-07-18

Last Posted Date: 2019-08-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 49

Registration Number: NCT03221179

Locations: 🇳🇱
PRA Health Sciences Early Development Services, Zuidlaren, Netherlands

Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Pirfenidone

First Posted Date: 2017-07-06

Last Posted Date: 2020-11-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT03208933

Locations: 🇷🇺
Regional State Budgetary Institution of Healthcare "Regional Cinilcal Hospital"; Pulmonology, Barnaul, Altaj, Russian Federation
🇷🇺
Pulmonologii NII FMBA of Russia, Moscow, Moskovskaja Oblast, Russian Federation
🇷🇺
Budget Institution of Healthcare of Voronezh Region "Voronezh Regional Clinical Hospital #1", Voronezh, Russian Federation

and more 8 locations

An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

Phase 3

Completed

Conditions: Giant Cell Arteritis

Interventions: Drug: Tocilizumab

First Posted Date: 2017-06-28

Last Posted Date: 2020-09-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 3

Registration Number: NCT03202368

Locations: 🇫🇷
Hopital Claude Huriez; Internal Medicine, Lille, France
🇫🇷
Hopital Emile Muller; Medecine Interne, Mulhouse, France
🇫🇷
Hopital La Cavale Blanche; Rhumatologie, Brest, France

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Phase 3

Completed

Conditions: Triple-negative Breast Cancer

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Drug: Placebo
Drug: Nab-paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Filgrastim
Drug: Pegfilgrastim

First Posted Date: 2017-06-23

Last Posted Date: 2023-10-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 333

Registration Number: NCT03197935

Locations: 🇩🇪
Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany
🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom
🇦🇺
Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia

and more 65 locations

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Phase 3

Active, not recruiting

Conditions: Neoplasms

Interventions: Drug: Alectinib
Drug: Crizotinib

First Posted Date: 2017-06-21

Last Posted Date: 2025-05-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 200

Registration Number: NCT03194893

Locations: 🇫🇷
Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac, France
🇭🇰
Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon, Hong Kong
🇮🇹
Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Roma, Lazio, Italy

and more 26 locations

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: Nab-Paclitaxel
Drug: Gemcitabine
Drug: Cobimetinib
Drug: PEGPH20
Drug: BL-8040
Drug: RO6874281
Drug: Atezolizumab
Drug: Oxaliplatin
Drug: Bevacizumab
Drug: Tocilizumab
Drug: AB928
Drug: Tiragolumab
Drug: Leucovorin
Drug: Selicrelumab
Drug: Fluorouracil

First Posted Date: 2017-06-20

Last Posted Date: 2025-04-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 341

Registration Number: NCT03193190

Locations: 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

and more 20 locations

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Drug: Emicizumab

First Posted Date: 2017-06-19

Last Posted Date: 2021-06-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 195

Registration Number: NCT03191799

Locations: 🇨🇦
Kaye Edmonton Clinic, Edmonton, Alberta, Canada
🇩🇪
Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin, Bonn, Germany
🇩🇪
Vivantes Klinikum im Friedrichshain - Landsberger Allee, Angiologie und Hämostaseologie, Berlin, Germany

and more 69 locations

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Drug: Vinorelbine
Drug: Gemcitabine

First Posted Date: 2017-06-19

Last Posted Date: 2024-10-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 453

Registration Number: NCT03191786

Locations: 🇩🇪
LungenClinic Großhansdorf GmbH; Klinische Forschung, Großhansdorf, Germany
🇦🇷
Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina
🇦🇷
Hospital Privado de Comunidad, Mar del Plata, Argentina

and more 88 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy